CIG
NVO

Cullen Investment Group’s Novo Nordisk NVO Stock Holding History

Cullen Investment Group’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$479K Hold
10,000
– – 0.06% 137
2026
Q1 		$368K Buy
+10,000
New +$474K 0.05% 145

Other funds holding NVO

SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
GA
GuoLine Advisory Singapore $1.07B AUM 26.27% 1-Year Est. Return
QI
QV Investors Calgary, Alberta, Canada $1.3B AUM 31.14% 1-Year Est. Return
AA
ABC Arbitrage Paris, France $926M AUM 45.9% 1-Year Est. Return
OFA
Oak Family Advisors Chicago, Illinois $391M AUM 26.35% 1-Year Est. Return
PFS
Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
AIP
ARS Investment Partners New York $2.29B AUM 113.95% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
ONB
Old National Bancorp Evansville, Indiana $5.02B AUM 25.65% 1-Year Est. Return

Cullen Investment Group's NVO Position: Q2 2026 in Review

Cullen Investment Group held its Novo Nordisk (NVO) position steady in Q2 2026 at 10,000 shares worth $479K. The position accounts for 0.06% of the portfolio, ranked #137.

Cullen Investment Group first reported a position in NVO in Q1 2026 and has held it in 2 quarters since. 309 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • Cullen Investment Group held 10,000 shares of Novo Nordisk worth $479K as of Q2 2026.
  • Cullen Investment Group left its Novo Nordisk share count unchanged in Q2 2026.
  • Novo Nordisk made up 0.06% of Cullen Investment Group's portfolio in Q2 2026, its #137 holding.
  • Cullen Investment Group first reported a position in Novo Nordisk in Q1 2026 and has held it in 2 quarters since.
  • 309 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Cullen Investment Group's 13F filing for Q2 2026, filed 9 Jul 2026.